Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 01, 2026
TickeronGET DAILY SIGNALS
ICLR vs RGEN: ICON and Repligen Offer Distinct Healthcare Opportunities

ICLR vs RGEN: ICON and Repligen Offer Distinct Healthcare Opportunities

Key Takeaways

  • ICLR (ICON plc) is a global contract research organization (CRO) with a large, visible backlog and consistent profitability, while RGEN (Repligen Corporation) is a life-sciences tools maker riding a bioprocessing recovery with faster organic growth.
  • Both names carry "Buy" analyst consensus, but ICLR offers steadier earnings visibility, whereas RGEN carries more acquisition and margin-related volatility.
  • Tickeron AI Verdict: ICLR currently ranks as the preferred ticker of the two, reflecting more consistent trend strength and stability.
  • Recent quarters show ICLR beating estimates and lifting guidance, while RGEN posted a record quarter and closed its BioLife acquisition.
  • For more detail on each name's latest developments, explore ICLR Major News and ICLR Today's Price Move, as well as RGEN Major News and RGEN Today's Price Move.
  • To see how automated systems are positioning across these and other stocks, explore Trending AI Robots.

Why Compare These Two Names

Investors comparing ICLR and RGEN are weighing two distinct ways to participate in healthcare and life sciences. ICON plc is a leading contract research organization (CRO) that helps pharmaceutical and biotechnology companies run clinical trials, while Repligen Corporation supplies the bioprocessing equipment and consumables used to manufacture biologic drugs. Though both sit within the broader healthcare ecosystem, their business models, growth drivers, and risk profiles differ meaningfully. This stock comparison is most relevant to growth-oriented investors and traders evaluating relative performance, market positioning, and which name offers a steadier risk-reward profile in the current environment. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

ICON plc (ICLR) Overview and Recent Performance

ICLR (ICON plc) is a Dublin-headquartered contract research organization (CRO) that provides outsourced clinical development services, spanning clinical trial management, laboratory services, data analytics, and regulatory consulting. The company operates across more than 50 countries with over 40,000 employees, serving large pharmaceutical, biotechnology, and medical device clients.

In recent weeks, ICON reported third-quarter results that came in ahead of consensus, with non-GAAP earnings per share (EPS) and revenue both beating expectations. Management highlighted net business wins of roughly $3.15 billion, a book-to-bill ratio of 1.56 times, and a closing backlog near $24.5 billion, and raised its full-year revenue guidance. This performance triggered a wave of analyst price-target increases from several major firms, reinforcing a broader "Buy" consensus. Relative performance has improved as investors look past earlier accounting-related concerns and focus on steady bookings and demand across large pharma and biotech clients. From what I see, the backlog provides solid visibility here.

Repligen Corporation (RGEN) Overview and Recent Performance

RGEN (Repligen Corporation) is a Waltham, Massachusetts-based life-sciences company that develops and commercializes bioprocessing technologies across four franchises: filtration and fluid management, chromatography, process analytics, and proteins. Its customers are primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs).

Repligen recently delivered what management called a record quarter, with revenue up roughly 11% year over year to about $209 million and organic growth of approximately 12.5%. Adjusted EPS beat consensus by a wide margin, and the company raised its full-year revenue and earnings outlook. Sentiment has also been shaped by the closing of the BioLife acquisition, which expands Repligen's footprint in high-growth cell therapy, and by a recovery in bioprocessing demand. However, the stock carries ongoing margin headwinds in its filtration segment, GAAP net losses tied to acquisition costs, and a $1 billion convertible-notes transaction that introduces potential dilution.

Automated Trading Systems Perspective

Tickeron operates hundreds of AI trading bots that collectively trade thousands of different tickers, each built around a distinct strategy, timeframe, and statistical profile. Because not every bot suits every market regime, Tickeron curates a dedicated Trending AI Robots page to spotlight the bots best aligned with current conditions. The bots available vary widely in trading style, holding period, and the set of tickers they cover, allowing users to compare performance metrics and statistics before engaging. Exploring this curated selection can help traders understand how automated, data-driven systems are approaching names like ICLR and RGEN relative to the broader market. To review the current lineup, visit the Trending AI Robots page.

Head-to-Head Comparison

The two companies differ fundamentally in what they sell and how they generate revenue. ICLR monetizes services tied to clinical trial execution, giving it a large contracted backlog and book-to-bill visibility that smooths near-term revenue. RGEN monetizes products and consumables consumed during biologic manufacturing, making it more sensitive to cyclical swings in bioprocessing demand but also a more direct play on manufacturing-volume growth.

On growth, RGEN currently shows faster organic expansion, helped by surging proteins and chromatography demand and the BioLife integration. ICLR shows more moderate single-digit revenue growth but stronger bottom-line consistency and GAAP profitability. Risk factors also diverge: ICON faces exposure to biotech funding cycles and lingering questions around earnings quality, while Repligen faces acquisition integration risk, filtration-segment softness, and near-term margin pressure. In sector terms, both are healthcare names, but ICON leans toward clinical development services and Repligen toward manufacturing tools, giving each a different sensitivity to the same biotech funding environment.

Tickeron AI Verdict

Based on observable factors, Tickeron's AI would likely favor ICLR at present. The assessment rests on more consistent trend strength, a large and visible backlog, a book-to-bill ratio well above 1.0, and steadier profitability, which together suggest greater stability and reduced downside variance relative to RGEN. Repligen offers a compelling growth catalyst through its BioLife acquisition and a recovering bioprocessing cycle, but its GAAP losses, margin headwinds, and recent convertible-notes dilution introduce more variability. The verdict reflects relative positioning rather than a definitive forecast, and market conditions can shift as new earnings and demand data emerge. I’m watching this closely as new data comes in.

Using Tickeron AI Tools for Deeper Analysis

In my own research process, I often turn to Tickeron’s AI Trading Bots to test how different strategies perform on names like these. The platform lets me review performance metrics across various timeframes and conditions, helping refine ideas without replacing core fundamental work. It adds a useful layer when comparing stability versus growth potential in the sector.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: RGEN, ICLR

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


RGEN in downward trend: 10-day moving average broke below 50-day moving average on November 11, 2026

The 10-day moving average for RGEN crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RGEN as a result. In 72 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for RGEN turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 41 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

RGEN moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 70 cases where RGEN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

Following a +6.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where RGEN advanced for three days, in 226 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

RGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. RGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.636) is normal, around the industry mean (4.964). RGEN has a moderately high P/E Ratio (234.446) as compared to the industry average of (40.591). Projected Growth (PEG Ratio) (1.935) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.006) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 9.78B. The market cap for tickers in the group ranges from 126 to 159.96B. ISRG holds the highest valuation in this group at 159.96B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -8%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 4%. STXS experienced the highest price growth at 12%, while RGNT experienced the biggest fall at -42%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 21%. For the same stocks of the Industry, the average monthly volume growth was 3% and the average quarterly volume growth was -39%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 53
Price Growth Rating: 52
SMR Rating: 81
Profit Risk Rating: 94
Seasonality Score: 18 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of biologic drugs

Industry PharmaceuticalsOther

Industry
Biotechnology
Address
41 Seyon Street
Phone
+1 781 250-0111
Employees
2000
Web
https://www.repligen.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.